aTyr Pharma, Inc. (ATYR)

aTyr Pharma, Inc. (ATYR) scores 26 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $0. Quantitative score: 44/100. Qualitative score: 20/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full ATYR analysis on boothcheck